期刊文献+

多巴胺D_3受体Ser9Gly多态性与利培酮治疗首发精神分裂症患者疗效关系 被引量:2

Relationship of efficacy of dopamine D_3 receptor Ser9Gly polymorphism and risperidone in the treatment of first episode schizophrenia patients
下载PDF
导出
摘要 目的探讨多巴胺D3受体基因多态性与首发精神分裂症患者精神症状严重度和抗精神病药疗效是否相关。方法对201例首发精神分裂症患者进行利培酮治疗[3~5 mg/d,平均(3.2±1.3)mg/d],疗程8周。采用聚合酶链反应限制性片段长度多态性技术检测多巴胺D3受体基因Ser9Gly多态性。并用阳性和阴性症状量表(PANSS)评定患者治疗前和治疗第8周末的精神症状,分析基因型及其他临床指标与PANSS分值和减分率的关系。结果多巴胺D3受体基因Ser9Gly基因型在各患者组分布频率均符合H-W平衡定律(P>0.05);基因型在治疗显效和未显效组分布频率的差异无统计学意义(χ2=1.995,P=0.369);各基因型亚组临床指标的差异均无统计学意义(均P>0.05);基因型与患者治疗前PANSS总分(χ2=6.605,P=0.018)、治疗第8周末PANSS总减分率(χ2=6.471,P=0.021)和阳性症状减分率(χ2=6.239,P=0.023)均有统计学意义。结论多巴胺D3受体基因Ser9Gly功能多态性可能影响首发精神分裂症患者对利培酮的治疗效应。 Objective To explore the relationship of efficacy of dopamine D3 receptor Ser9Gly polymorphism and risperidone in the treatment of first episode schizophrenia patients.Methods 201 cases of first episode schizophrenia patients were received risperidone treatment [3-5 mg/d,average(3.2±1.3) mg/d],for 8 weeks.The Ser9Gly dopamine D3 receptor gene polymorphism of 201 patients was detected by polymerase chain reaction-restriction fragment length polymorphism.And the psychiatric symptoms of patients before treatment and the treatment of the 8th week was assessed by PANSS.The relationship of genotype and other clinical indicators and PANSS score and reduced rate was analyzed by us.Results Dopamine D3 receptor gene Ser9Gly genotype distribution frequency in each patient group were in line with the HW equilibrium(P 0.05);genotype in the treatment of cured and not cured groups of the frequency difference not statistically significant(χ2 = 1.995,P = 0.369);clinical indicators of each genotype subgroup difference were not statistically significant(P 0.05);genotype with patients before treatment,PANSS total scores(χ2 = 6.605,P = 0.018),PANSS total reduction in treatment at week 8 pointsrate(χ2 = 6.471,P = 0.021) and positive symptom reduction rate(χ2 = 6.239,P = 0.023) were significantly statistically significant.Conclusion Functional polymorphism of the dopamine D3 receptor gene Ser9Gly may affect the first episode schizophrenia treatment effect of risperidone.
出处 《中国医药导报》 CAS 2012年第33期18-21,共4页 China Medical Herald
基金 国家十一五重大基础研究与发展项目(2007BAI07B01) 973项目(2009CB52000) 广东省清远市科技计划项目(2010B92)
关键词 精神分裂症 多巴胺D3受体 Ser9Gly多态性 利培酮 Schizophrenia Dopamine D3 receptor Ser9Gly polymorphism Risperidone
  • 相关文献

参考文献16

  • 1Le CM,Skoloff P,Hillion, et al. Chromosomal localization of the human D3 dopamine receptor gene [J]. Hum Genet, 1991,87 : 618-629.
  • 2中华医学会精神科分会.CCMD-3中国精神障碍分类与诊断标准[M].山东:山东科学技术出版社,2001:78-78.
  • 3张明廉,袁国桢,姚建军,钱永潮,倪素琴,刘雨生,蒋辛衍,周德祥.精神分裂症患者奥氮平治疗的血药浓度与剂量及临床效应的关系[J].中华精神科杂志,2003,36(3):139-142. 被引量:11
  • 4Gareth E ,Ian J,Fiona MC ,et al. Allelic variation of a Bal I polymorphism in the DRD3 gene does not influence susceptibility to bipolar disorder: results of analysis and meta-analysis [J]. Am J Med Genet,2001,105:307- 331.
  • 5王建,刘焯霖,陈彪.多巴胺D_3受体基因多态性与帕金森病[J].中国新药与临床杂志,2000,19(2):108-110. 被引量:2
  • 6Schwartz JC, Diaz J, Pilon, et al. Possible implications of the dopamine D3 receptor in schizophrenia and in antipsychotic drug actions [J]. Brain Res Rev, 2009,31 : 277-287.
  • 7Wang YH, Li WQ, Huang Z,et al. 5-HT2A receptor gene polymorphism and negative symptoms in first episode (drug-naive)Chinese Han nation- ality individuals with schizophrenia [J]. Journal of Central South Univer- sity,2008,33 : 293-296.
  • 8Crocq MA,Mant R,Asherson P, et al. Association between schizophre- nia and homozygosity at the dopamine D3 receptor gene [J]. J Med Genet, 1992,29: 258-860.
  • 9Ebstein RP,Macciardi F,Heresco LU. Evidence for an association be- tween the dopamine D3 receptor gene DRD3 and schizophrenia [J]. Hum Hered, 1997,47 ( 1 ) : 6-16.
  • 10Ishiguro H,Okuyama Y,Tom M. Mutation and association analysis of the 5" region of the dopamine D3 receptor gene in schizophrenia pa- tients:identification of the Ala38Thr polymorphism and suggested as- sociation between DRD3 haplotypes and schizophrenia [J]. Mol Psychi- atry ,2010,5 (4) :433-438.

二级参考文献28

  • 1周儒伦,周朝凤,王玉凤,沈渔,范建华.多巴胺D_2受体基因多态性与精神分裂症的关系[J].北京医科大学学报,1996,28(1):23-25. 被引量:2
  • 2杨玲玲.影响药物作用的因素和临床用药原则[A].见:王祖新主编.临床精神药理学[C].北京:北京医科大学、中国协和医科大学联合出版社,1990.62-68.
  • 3Sanger TM, Lieberman JA, Tohen M, et al. Olanzapine versus haloperidol treatment in first episode psychosis. Am J Psychiatry,1999,156:79-87.
  • 4Tollefson GD, Sanger riM. Negative symptoms: a path analytic approach to a double-build, placebo and haloperidol controlled clinical trial with olanzapine, Am J psychiatry, 1997,154:466-474.
  • 5Olesen OV, linet K. Determination of olanzapine in serum by HPLC using ultraviolet detection considering the easy oxidability of the compound and the presence of other psychotropic drugs. J Chromatogr B Biomed Sci Appl,1998,714:309-315.
  • 6Midha KIC Intersubjeet variation in the pharmacokinetics of haloperidol and reduced holoperidol. J Clin Psychoparmacol, 1999,9:98-99.
  • 7Perry PJ, Sanger T, Beasley C. Olanzapine plasma concentrations and clinical response in acutely schizophrenic patients. J Chin Psychopharmacol, 1997,17:472-477.
  • 8Beasley CM, Tollefson GD, Tran PV. Safety of olanzapine. J clin Psychiatry, 1997,58 Suppl 10:13-17.
  • 9Gareth Elvidge,Ian Jones,Fiona Mc Candless,et al.Allelic variation of a BalI polymorphism in the DRD3 gene does not influence susceptibility to bipolar disorder:results of analysis and meta-analysis[J].Am J Med Genet,2001,105:307-331.
  • 10Schwartz JC,Diaz J,Pilon,et al.Possible implications of the dopamine D3 receptor in schizophrenia and in antipsychotic drug actions[J].Brain Res Rev,2000,31:277-287.

共引文献40

同被引文献19

引证文献2

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部